Oncologists recommend chemotherapy because, for many cancers, it remains the most effective tool available to shrink tumors, prevent recurrence, or extend life. But the feeling that it’s being “pushed” is common and worth unpacking. The answer involves a mix of genuine medical evidence, financial incentives baked into the system, legal pressures on doctors, and communication gaps that can make a recommendation feel like a directive.
How Chemotherapy Works Against Cancer
Cancer cells divide rapidly and without the normal controls that keep healthy cells in check. Chemotherapy drugs exploit that vulnerability. Some damage the DNA inside cancer cells so they can’t replicate. Others block the raw materials cells need to build new DNA, or interfere with the molecular machinery that pulls cells apart during division. Because cancer cells are dividing faster than most healthy tissue, they’re more sensitive to these attacks.
This isn’t a subtle mechanism. It’s blunt, which is why side effects can be severe. But that bluntness is also why chemotherapy remains a frontline option for aggressive, fast-growing tumors where precision therapies either don’t exist yet or haven’t proven as effective on their own.
The Evidence Behind the Recommendation
Chemotherapy is used in several distinct ways, and the strength of evidence varies depending on the goal.
Before surgery (neoadjuvant): Chemotherapy can shrink a tumor enough to make surgery possible or less invasive. In breast cancer, about 75% of patients who were initially ineligible for breast-conserving surgery became eligible after pre-surgical chemotherapy, based on a study of 600 patients. Overall, roughly 57% of breast cancer patients see the kind of uniform tumor shrinkage that makes them ideal candidates for less extensive surgery. The response varies by cancer subtype: triple-negative breast cancers shrink this way about 66% of the time, while hormone-receptor-positive cancers respond at closer to 46%.
After surgery (adjuvant): The goal here is to kill any microscopic cancer cells that may have spread before the tumor was removed. For cancers like stage II and III breast and colon cancer, adjuvant chemotherapy meaningfully reduces the risk of the cancer coming back. When your oncologist says “we got it all, but I recommend chemo,” they’re playing the odds against invisible disease.
For advanced or metastatic cancer: When a cure isn’t realistic, chemotherapy can slow progression and extend life, sometimes by months, sometimes by years depending on the cancer type. This is where the conversation about trade-offs gets most personal, because the benefits need to be weighed against the toll on quality of life.
Why Not Just Use Immunotherapy Instead?
Newer treatments like immunotherapy get a lot of attention, and for good reason. In advanced non-small cell lung cancer, for example, immunotherapy alone is now a standard first-line option for patients whose tumors express high levels of a specific protein marker called PD-L1. Many oncologists prefer immunotherapy by itself in these cases because it’s better tolerated and patients report improved quality of life compared to chemotherapy combinations.
But chemotherapy hasn’t been replaced. Oncologists often prefer combining chemotherapy with immunotherapy for patients who have a high disease burden, aggressive tumor growth, or significant symptoms. Patients with rapidly progressing cancer may not have time to wait and see if immunotherapy alone will work. The latest ASCO guidelines for lung cancer with specific genetic mutations now recommend combinations of targeted therapy plus chemotherapy as a first-line approach for certain patients, reflecting data from recent clinical trials showing improved outcomes.
For many cancer types, immunotherapy simply doesn’t work well or doesn’t have approval yet. Chemotherapy remains the backbone of treatment for most blood cancers, many gastrointestinal cancers, and ovarian cancer, among others. When an oncologist recommends chemo over a newer option, it’s often because the evidence for chemo is stronger for that particular cancer.
The Financial Incentive That Does Exist
There is a real financial structure worth knowing about. In the United States, most oncology practices operate under a “buy-and-bill” model for drugs administered in the office. The practice purchases chemotherapy drugs, administers them, and then bills Medicare or private insurance. Medicare reimburses these drugs at the average sales price plus 6%. That means more expensive drugs generate more revenue for the practice.
This doesn’t mean your oncologist is prescribing chemo you don’t need to pad the bottom line. But it does mean the system creates a financial incentive that doesn’t exist for, say, recommending surgery (performed by a surgeon) or radiation (performed at a separate facility) or watchful waiting (which generates no revenue at all). Health policy researchers have raised concerns about this model for years, and some newer payment models are being tested to decouple drug cost from practice revenue. It’s a systemic issue, not typically an individual act of bad faith.
Legal Pressure to Recommend Treatment
Oncologists practice within a framework of national guidelines published by organizations like ASCO and the NCCN. These guidelines represent the consensus of expert panels reviewing the best available evidence. When chemotherapy is listed as the standard of care for a particular cancer type and stage, an oncologist who doesn’t recommend it takes on legal risk. An oncologist could be held liable for omitting indicated testing or neglecting standard treatment protocols. If a patient’s cancer recurs and the oncologist hadn’t recommended guideline-concordant chemotherapy, that’s a malpractice exposure.
This creates a dynamic where even an oncologist who personally suspects the benefit is marginal for a specific patient may still present chemotherapy as the recommended path. Following published guidelines provides legal protection. Deviating from them requires careful documentation and a clear rationale.
When a Recommendation Feels Like Pressure
Research on oncologist-patient communication reveals a gap. Many oncologists report feeling inadequately trained in shared decision-making, the practice of presenting options, discussing trade-offs, and helping patients choose based on their own values. Meanwhile, many cancer patients report feeling less involved in their care decisions than they want to be.
Cancer decisions are deeply personal. They depend on your life stage, your fears about side effects, your anxiety about recurrence, and what quality of life means to you. But you’re often making these decisions in a new, emotional situation where you haven’t had time to form clear preferences. An oncologist who presents a strong recommendation with confidence and urgency may be genuinely trying to give you the best chance, but if they skip the conversation about trade-offs, it can feel like being pushed rather than guided.
A few things can help. Ask your oncologist what the specific expected benefit is, in numbers: how much does this reduce my recurrence risk, or how many months of life extension are we talking about? Ask what happens if you don’t do chemo. Ask about the side effect profile for the specific regimen being recommended. A good oncologist will welcome these questions. If yours doesn’t, a second opinion from another oncologist at a different institution can provide clarity without burning any bridges.
What’s Actually Happening in Most Cases
The majority of chemotherapy recommendations are grounded in evidence that the treatment improves survival, reduces recurrence, or enables less aggressive surgery. The oncologist has likely seen the data, treated hundreds of similar patients, and is recommending what the evidence supports. At the same time, the system they work within has financial structures, legal incentives, and communication norms that can all make recommendations feel more like mandates than options. Both things are true simultaneously.
The most productive approach is to treat chemotherapy recommendations as what they are: an expert opinion you’re entitled to interrogate. Ask for the numbers. Understand the goal of treatment, whether it’s curative or palliative. And recognize that declining or delaying is always your right, but it’s a decision best made with full information rather than suspicion alone.